Intrexon (NYSE: XON) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Volatility & Risk
Intrexon has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Codexis has a beta of -1.58, indicating that its share price is 258% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Intrexon and Codexis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon presently has a consensus price target of $38.50, suggesting a potential upside of 197.53%. Codexis has a consensus price target of $7.81, suggesting a potential upside of 18.37%. Given Intrexon’s stronger consensus rating and higher possible upside, analysts plainly believe Intrexon is more favorable than Codexis.
Insider & Institutional Ownership
77.5% of Intrexon shares are owned by institutional investors. Comparatively, 65.7% of Codexis shares are owned by institutional investors. 56.3% of Intrexon shares are owned by company insiders. Comparatively, 9.8% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Intrexon and Codexis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Intrexon and Codexis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intrexon||$190.93 million||8.18||-$186.61 million||($1.12)||-11.55|
|Codexis||$48.84 million||6.53||-$8.55 million||($0.65)||-10.15|
Codexis has lower revenue, but higher earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.
Intrexon beats Codexis on 11 of the 13 factors compared between the two stocks.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.